Approximate initial concentration (in mol m−3) at distinct time points on the endothelial toxicity contour line for paclitaxel and sirolimus release strategy optimization.

Summary of lipolysis extent at the change point and theoretical optimal dose (TOD) to obtain lipolysis extent of 90%.

Joaquim Calvo-Lerma (6393341)
Victoria Fornés-Ferrer (4162279)
Irene Peinado (6393344)
Ana Heredia (4510555)
Carmen Ribes-Koninckx (333629)
Ana Andrés (6393347)

February 2019

Summary of lipolysis extent at the change point and theoretical optimal dose (TOD) to obtain lipolys...

PK profiles of individual drugs in at-risk patients relative to MIC.

Natasha Strydom (6541475)
Sneha V. Gupta (1454824)
William S. Fox (6541478)
Laura E. Via (315019)
Hyeeun Bang (6541481)
Myungsun Lee (384428)
Seokyong Eum (1604707)
TaeSun Shim (1604719)
Clifton E. Barry III (197104)
Matthew Zimmerman (2827673)
Véronique Dartois (193696)
Radojka M. Savic (2735914)

April 2019

One thousand patients were simulated using the established model and the fifth percentile of lower e...

Optimal concentration of each kinase inhibitor for PC9 cancer cell line treatment.

Hongwei Shao (493627)
Tao Peng (81319)
Zhiwei Ji (493628)
Jing Su (23377)
Xiaobo Zhou (10386)

December 2013

Optimal concentration of each kinase inhibitor for PC9 cancer cell line treatment.</p

Contour plots of the cost function for paclitaxel (left column) and sirolimus (right column) over the design space consisting of initial concentration in the stent polymerc0 and release timetE.

Franz Bozsak (755922)
David Gonzalez-Rodriguez (728450)
Zachary Sternberger (755923)
Paul Belitz (755924)
Thomas Bewley (755925)
Jean-Marc Chomaz (755926)
Abdul I. Barakat (25391)

June 2015

The scale for the cost function representation is truncated at a maximum of 1; all values larger ...

Release kinetics and resulting cost function scores and normalized concentration distributions for repesentative designs of quasi-bolus, first-order, and zero-order drug release.

Franz Bozsak (755922)
David Gonzalez-Rodriguez (728450)
Zachary Sternberger (755923)
Paul Belitz (755924)
Thomas Bewley (755925)
Jean-Marc Chomaz (755926)
Abdul I. Barakat (25391)

June 2015

A: Release profiles as quantified by the time evolution of the remaining mass percentage o...

Contour plots of the effect of the presence of SMCs in the SES on the cost function for paclitaxel (left column) and sirolimus (right column) over the design space consisting of initial concentration in the stent polymerc0 and release timetE.

Franz Bozsak (755922)
David Gonzalez-Rodriguez (728450)
Zachary Sternberger (755923)
Paul Belitz (755924)
Thomas Bewley (755925)
Jean-Marc Chomaz (755926)
Abdul I. Barakat (25391)

June 2015

The scale for the cost function representation is truncated at a maximum of 1; all values larger ...

Concentration profiles of tumor cells at different times.

Kang-Ling Liao (535938)
Xue-Feng Bai (333686)
Avner Friedman (54903)

March 2014

(A), (B), and (C) are the concentration profiles of at times weeks (short time), weeks (time a...

Summary of Drug Titrations Showing 50% Inhibitory Concentration, IC50, for the P-gp± Cell Lines Treated with Paclitaxel and Derivatives (and ± Verapamil).

Marc St. George (318231)
Ahmed T. Ayoub (747972)
Asok Banerjee (751487)
Cassandra D. M. Churchill (751488)
Philip Winter (291799)
Mariusz Klobukowski (747973)
Carol E. Cass (102519)
Richard F. Ludueña (751489)
Jack A. Tuszynski (160860)
Sambasivarao Damaraju (102523)

June 2015

The IC50 values are given in nM. Values and errors (SE) shown are representative of n ...

Summary of Drug Titrations Showing 50% Inhibitory Concentration, IC50, in Breast Cancer Cell Lines Treated with Paclitaxel and Analogs.

Marc St. George (318231)
Ahmed T. Ayoub (747972)
Asok Banerjee (751487)
Cassandra D. M. Churchill (751488)
Philip Winter (291799)
Mariusz Klobukowski (747973)
Carol E. Cass (102519)
Richard F. Ludueña (751489)
Jack A. Tuszynski (160860)
Sambasivarao Damaraju (102523)

June 2015

The IC50 values are given in nM. Values and errors (SE) shown are representative of n ...

Time evolution of the normalized drug concentration and relative linear fitting.

Per Thomas Haga (3839038)
Giulia Pizzichelli (3839035)
Mikael Mortensen (3828058)
Miroslav Kuchta (3828076)
Soroush Heidari Pahlavian (548221)
Edoardo Sinibaldi (597634)
Bryn A. Martin (292319)
Kent-Andre Mardal (3211215)

March 2017

The blue lines represent the time evolution of the normalized drug concentration at different cro...

Spatial-temporal evolution of the drug concentration in the tumor model.

Hang Xie (218360)
Yang Jiao (147576)
Qihui Fan (1867066)
Miaomiao Hai (5900576)
Jiaen Yang (778079)
Zhijian Hu (1528558)
Yue Yang (52715)
Jianwei Shuai (773992)
Guo Chen (182090)
Ruchuan Liu (472818)
Liyu Liu (339838)

October 2018

(a) and (b) the drug concentration distribution in an ideal tumor with r0 = 0.2 cm and σ = 0.01 cm. ...

Spatial-temporal evolution of the drug concentration in ideal isotropic tumors under different periodic dosing conditions.

Hang Xie (218360)
Yang Jiao (147576)
Qihui Fan (1867066)
Miaomiao Hai (5900576)
Jiaen Yang (778079)
Zhijian Hu (1528558)
Yue Yang (52715)
Jianwei Shuai (773992)
Guo Chen (182090)
Ruchuan Liu (472818)
Liyu Liu (339838)

October 2018

(a) and (b) are associated with the vascularized micro-environment with quick drug decay (τdecay = 6...

Simplified Equations Using Two Concentrations To Calculate Area under the Curve for Antimicrobials with Concentration-Dependent Pharmacodynamics: Daptomycin as a Motivating Example

M.p. Pai
A. Russo
A. Novelli
Mario Venditti
Marco Falcone

January 2014

The effects of several antimicrobial agents are predicted by the ratio of the area under the concent...

Intratissular PpIX concentrations as a function of tumor depth after m-ALA topical application.

Lea Leufflen (5194751)
Aurelie Francois (5194748)
Julia Salleron (175147)
Catherine Barlier (5194754)
Gilles Dolivet (336835)
Frederic Marchal (5194745)
Lina Bezdetnaya (309326)

May 2018

Intratissular PpIX concentrations as a function of tumor depth after m-ALA topical application.</...

(A) Peak intracellular tumor tissue concentration of bioavailable DOX, and (B) ratio of peak bioavailable tumor tissue concentration to peak cardiac tissue concentration, presented for all DOX formulations.

Astrid Gasselhuber (127296)
Matthew R. Dreher (127300)
Frank Rattay (127304)
Bradford J. Wood (127308)
Dieter Haemmerich (52592)

October 2012

(A) Peak intracellular tumor tissue concentration of bioavailable DOX, and (B) ratio of peak bioa...

Summary of lipolysis extent at the change point and theoretical optimal dose (TOD) to obtain lipolysis extent of 90%.

Joaquim Calvo-Lerma (6393341)
Victoria Fornés-Ferrer (4162279)
Irene Peinado (6393344)
Ana Heredia (4510555)
Carmen Ribes-Koninckx (333629)
Ana Andrés (6393347)

February 2019

Summary of lipolysis extent at the change point and theoretical optimal dose (TOD) to obtain lipolys...

PK profiles of individual drugs in at-risk patients relative to MIC.

Natasha Strydom (6541475)
Sneha V. Gupta (1454824)
William S. Fox (6541478)
Laura E. Via (315019)
Hyeeun Bang (6541481)
Myungsun Lee (384428)
Seokyong Eum (1604707)
TaeSun Shim (1604719)
Clifton E. Barry III (197104)
Matthew Zimmerman (2827673)
Véronique Dartois (193696)
Radojka M. Savic (2735914)

April 2019

One thousand patients were simulated using the established model and the fifth percentile of lower e...

Optimal concentration of each kinase inhibitor for PC9 cancer cell line treatment.

Hongwei Shao (493627)
Tao Peng (81319)
Zhiwei Ji (493628)
Jing Su (23377)
Xiaobo Zhou (10386)

December 2013

Optimal concentration of each kinase inhibitor for PC9 cancer cell line treatment.</p

Contour plots of the cost function for paclitaxel (left column) and sirolimus (right column) over the design space consisting of initial concentration in the stent polymerc0 and release timetE.

Franz Bozsak (755922)
David Gonzalez-Rodriguez (728450)
Zachary Sternberger (755923)
Paul Belitz (755924)
Thomas Bewley (755925)
Jean-Marc Chomaz (755926)
Abdul I. Barakat (25391)

June 2015

The scale for the cost function representation is truncated at a maximum of 1; all values larger ...

Release kinetics and resulting cost function scores and normalized concentration distributions for repesentative designs of quasi-bolus, first-order, and zero-order drug release.

Franz Bozsak (755922)
David Gonzalez-Rodriguez (728450)
Zachary Sternberger (755923)
Paul Belitz (755924)
Thomas Bewley (755925)
Jean-Marc Chomaz (755926)
Abdul I. Barakat (25391)

June 2015

A: Release profiles as quantified by the time evolution of the remaining mass percentage o...

Contour plots of the effect of the presence of SMCs in the SES on the cost function for paclitaxel (left column) and sirolimus (right column) over the design space consisting of initial concentration in the stent polymerc0 and release timetE.

Franz Bozsak (755922)
David Gonzalez-Rodriguez (728450)
Zachary Sternberger (755923)
Paul Belitz (755924)
Thomas Bewley (755925)
Jean-Marc Chomaz (755926)
Abdul I. Barakat (25391)

June 2015

The scale for the cost function representation is truncated at a maximum of 1; all values larger ...

Concentration profiles of tumor cells at different times.

Kang-Ling Liao (535938)
Xue-Feng Bai (333686)
Avner Friedman (54903)

March 2014

(A), (B), and (C) are the concentration profiles of at times weeks (short time), weeks (time a...

Summary of Drug Titrations Showing 50% Inhibitory Concentration, IC50, for the P-gp± Cell Lines Treated with Paclitaxel and Derivatives (and ± Verapamil).

Marc St. George (318231)
Ahmed T. Ayoub (747972)
Asok Banerjee (751487)
Cassandra D. M. Churchill (751488)
Philip Winter (291799)
Mariusz Klobukowski (747973)
Carol E. Cass (102519)
Richard F. Ludueña (751489)
Jack A. Tuszynski (160860)
Sambasivarao Damaraju (102523)

June 2015

The IC50 values are given in nM. Values and errors (SE) shown are representative of n ...

Summary of Drug Titrations Showing 50% Inhibitory Concentration, IC50, in Breast Cancer Cell Lines Treated with Paclitaxel and Analogs.

Marc St. George (318231)
Ahmed T. Ayoub (747972)
Asok Banerjee (751487)
Cassandra D. M. Churchill (751488)
Philip Winter (291799)
Mariusz Klobukowski (747973)
Carol E. Cass (102519)
Richard F. Ludueña (751489)
Jack A. Tuszynski (160860)
Sambasivarao Damaraju (102523)

June 2015

The IC50 values are given in nM. Values and errors (SE) shown are representative of n ...

Time evolution of the normalized drug concentration and relative linear fitting.

Per Thomas Haga (3839038)
Giulia Pizzichelli (3839035)
Mikael Mortensen (3828058)
Miroslav Kuchta (3828076)
Soroush Heidari Pahlavian (548221)
Edoardo Sinibaldi (597634)
Bryn A. Martin (292319)
Kent-Andre Mardal (3211215)

March 2017

The blue lines represent the time evolution of the normalized drug concentration at different cro...

Spatial-temporal evolution of the drug concentration in the tumor model.

Hang Xie (218360)
Yang Jiao (147576)
Qihui Fan (1867066)
Miaomiao Hai (5900576)
Jiaen Yang (778079)
Zhijian Hu (1528558)
Yue Yang (52715)
Jianwei Shuai (773992)
Guo Chen (182090)
Ruchuan Liu (472818)
Liyu Liu (339838)

October 2018

(a) and (b) the drug concentration distribution in an ideal tumor with r0 = 0.2 cm and σ = 0.01 cm. ...

Spatial-temporal evolution of the drug concentration in ideal isotropic tumors under different periodic dosing conditions.

Hang Xie (218360)
Yang Jiao (147576)
Qihui Fan (1867066)
Miaomiao Hai (5900576)
Jiaen Yang (778079)
Zhijian Hu (1528558)
Yue Yang (52715)
Jianwei Shuai (773992)
Guo Chen (182090)
Ruchuan Liu (472818)
Liyu Liu (339838)

October 2018

(a) and (b) are associated with the vascularized micro-environment with quick drug decay (τdecay = 6...

Simplified Equations Using Two Concentrations To Calculate Area under the Curve for Antimicrobials with Concentration-Dependent Pharmacodynamics: Daptomycin as a Motivating Example

M.p. Pai
A. Russo
A. Novelli
Mario Venditti
Marco Falcone

January 2014

The effects of several antimicrobial agents are predicted by the ratio of the area under the concent...

Intratissular PpIX concentrations as a function of tumor depth after m-ALA topical application.

Lea Leufflen (5194751)
Aurelie Francois (5194748)
Julia Salleron (175147)
Catherine Barlier (5194754)
Gilles Dolivet (336835)
Frederic Marchal (5194745)
Lina Bezdetnaya (309326)

May 2018

Intratissular PpIX concentrations as a function of tumor depth after m-ALA topical application.</...

(A) Peak intracellular tumor tissue concentration of bioavailable DOX, and (B) ratio of peak bioavailable tumor tissue concentration to peak cardiac tissue concentration, presented for all DOX formulations.

Astrid Gasselhuber (127296)
Matthew R. Dreher (127300)
Frank Rattay (127304)
Bradford J. Wood (127308)
Dieter Haemmerich (52592)

October 2012

(A) Peak intracellular tumor tissue concentration of bioavailable DOX, and (B) ratio of peak bioa...

Summary of lipolysis extent at the change point and theoretical optimal dose (TOD) to obtain lipolysis extent of 90%.

Joaquim Calvo-Lerma (6393341)
Victoria Fornés-Ferrer (4162279)
Irene Peinado (6393344)
Ana Heredia (4510555)
Carmen Ribes-Koninckx (333629)
Ana Andrés (6393347)

February 2019

Summary of lipolysis extent at the change point and theoretical optimal dose (TOD) to obtain lipolys...

PK profiles of individual drugs in at-risk patients relative to MIC.

Natasha Strydom (6541475)
Sneha V. Gupta (1454824)
William S. Fox (6541478)
Laura E. Via (315019)
Hyeeun Bang (6541481)
Myungsun Lee (384428)
Seokyong Eum (1604707)
TaeSun Shim (1604719)
Clifton E. Barry III (197104)
Matthew Zimmerman (2827673)
Véronique Dartois (193696)
Radojka M. Savic (2735914)

April 2019

One thousand patients were simulated using the established model and the fifth percentile of lower e...

Optimal concentration of each kinase inhibitor for PC9 cancer cell line treatment.

Hongwei Shao (493627)
Tao Peng (81319)
Zhiwei Ji (493628)
Jing Su (23377)
Xiaobo Zhou (10386)

December 2013

Optimal concentration of each kinase inhibitor for PC9 cancer cell line treatment.</p

Approximate initial concentration (in mol m<sup>−3</sup>) at distinct time points on the endothelial toxicity contour line for paclitaxel and sirolimus release strategy optimization.

Abstract

Extracted data

Approximate initial concentration (in mol m<sup>−3</sup>) at distinct time points on the endothelial toxicity contour line for paclitaxel and sirolimus release strategy optimization.

Abstract

Extracted data

Related items

Related items